BASF Expands Innovation Campus Asia Pacific in Shanghai
BASF, the world’s leading chemical company, today broke ground on the second phase of its Innovation Campus Asia Pacific at its Pudong site in Shanghai, China. The €90 million expansion consists of an additional regional R&D building and auxiliary facilities and it will be completed by the end of 2015.
“By 2020, around 25% of BASF’s R&D employees will be located in Asia Pacific. The expansion reinforces BASF’s commitment to globalising its R&D activities and capturing growth opportunities in China and Asia Pacific,” said Dr Andreas Kreimeyer, member of the Board of Executive Directors of BASF SE and Research Executive Director.
The Innovation Campus is BASF’s most important R&D center in the region and is expected to become one of its largest R&D sites outside of Germany. With the expansion, BASF’s regional research capabilities will be further strengthened, focusing primarily on advanced materials and systems, as well as adding new areas such as formulations and chemical process and engineering serving growth industries such as automotive, construction, health and nutrition, and home and personal care.
“The Innovation Campus Asia Pacific in Shanghai has proven to be an effective platform that not only responds quickly to market needs in China and Asia Pacific, but also connects BASF with the science community in Asia Pacific. The enthusiasm for innovation among our colleagues, customers and partners is the cornerstone of solutions for a sustainable future in the region,” said Dr Martin Brudermüller, Vice Chairman of the Board of Executive Directors of BASF SE, responsible for Asia Pacific.
In Asia, in addition to the Innovation Campus in Shanghai, BASF also has R&D centers in Japan, Singapore and Korea. An Innovation Campus in India is also planned. BASF increased global spending on R&t to €1.8 billion in 2013 (2012: €1.7 billion), with around 10,650 scientists and researchers working in 3000 research projects. With 1300 patents filed last year and about 151,000 registrations and intellectual property rights worldwide, BASF is at the top of the global Patent Asset Index for the fifth time in succession.
Related News
-
News Women in Pharma: Hiring Across the Gender Divide
In our monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
Sponsored Content Ashwagandha and Herbal Medicines: Pharma’s Next Big Opportunity
Herbal medicines and nutraceuticals have seen a surge in interest since the onset of the COVID-19 pandemic. Driven by patient interest in prioritising personalised and integrative medicines, the herbal ingredients industry is now faced with concerns pe... -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News Updated – Changing abortion pill access according to the US FDA and Supreme Court
After the approval of the medical abortion pill, mifepristone, by the US FDA, states across the USA approach the distribution of the pill differently, some ruling against allowing access to the drug. -
News Revolutionising cancer treatment with mRNA-based therapeutics
Global market for mRNA-based oncology therapeutics expected to reach USD $2 billion by 2029, with promising results for the combination of mRNA candidates with immune checkpoint inhibitors to treat solid tumours. -
News Breaking Barriers: Innovations in Oral Solid Dose Form Bioavailability
The effectiveness of a medication often hinges on its bioavailability – the rate and extent at which the active ingredient is absorbed into the bloodstream. When it comes to oral solid dose forms, such as tablets and capsules, the challenge lies ... -
News Choosing the Right CDMO Partner: A Comprehensive Guide
Finding the right partner for the development and manufacturing of your pharmaceutical or biopharmaceutical products is paramount. This is where Contract Development and Manufacturing Organizations (CDMOs) step in, offering their expertise and infrastr...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance